• RF Acquisition Corp. II posted net income of USD 93,702 for quarter ended March 31, 2026, down from USD 1.02 million a year earlier.
• Interest income from cash held in trust fell to USD 454,296 from USD 1.23 million, while general, administrative and operating costs climbed to USD 360,594 from USD 213,238.
• Cash used in operating activities increased to USD 267,646 from USD 146,448, with cash held outside trust at USD 34,737 at quarter-end.
• Trust Account balance stood at USD 52.89 million as of March 31, 2026, following redemptions that removed about USD 71.58 million and left 4,831,265 public shares subject to possible redemption.
• On deal progress, RF Acquisition entered a business combination agreement with Nanyang Biologics and NYB Holdings, with Nanyang funding extension payments including USD 60,000 deposited after quarter-end to extend deadline to May 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RF Acquisition Corp. II published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-004763), on May 07, 2026, and is solely responsible for the information contained therein.